Clinical Trials
2 trialsNCT00121719 2023-06-22
An Open Label Dose Escalation Study Of E7080
Eisai Inc.
Phase 1 Completed
NCT02578316 2017-06-20
A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.
Eisai Inc.
Phase 1 Completed